Morphologic and cytogenetic characteristics of 184 evaluable patients and prognostic classification according to the IPSS number for 115 patients with MDS with evaluable karyotype
| Characteristics . | No. (%) . |
|---|---|
| FAB classification | |
| RA/RARS | 8 (4.3) |
| RAEB less than 10% blasts | 11 (6.0) |
| RAEB 10% blasts or more | 43 (23.4) |
| RAEBt | 60 (32.6) |
| CMML | 16 (8.7) |
| AML after MDS | 46 (25.0) |
| Cytogenetic characteristics* | |
| No sufficient cytogenetic data† | 33 (18) |
| Successful cytogenetic examination | 151 (82) |
| Good | 71 (47.0) |
| Intermediate | 34 (22.5) |
| Poor | 46 (30.5) |
| IPSS classification | |
| Low-risk group (0 points) | 1 (0.9) |
| Intermediate-1 group (0.5-1.0 points) | 11 (9.6) |
| Intermediate-2 group (1.5-2.0 points) | 48 (41.7) |
| High-risk group (> 2 points) | 55 (47.8) |
| Characteristics . | No. (%) . |
|---|---|
| FAB classification | |
| RA/RARS | 8 (4.3) |
| RAEB less than 10% blasts | 11 (6.0) |
| RAEB 10% blasts or more | 43 (23.4) |
| RAEBt | 60 (32.6) |
| CMML | 16 (8.7) |
| AML after MDS | 46 (25.0) |
| Cytogenetic characteristics* | |
| No sufficient cytogenetic data† | 33 (18) |
| Successful cytogenetic examination | 151 (82) |
| Good | 71 (47.0) |
| Intermediate | 34 (22.5) |
| Poor | 46 (30.5) |
| IPSS classification | |
| Low-risk group (0 points) | 1 (0.9) |
| Intermediate-1 group (0.5-1.0 points) | 11 (9.6) |
| Intermediate-2 group (1.5-2.0 points) | 48 (41.7) |
| High-risk group (> 2 points) | 55 (47.8) |